Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.81 |
| ▸ | ESRRG | P62508 | 4/20 | 0.48 |
| ▸ | ESRRB | O95718 | 2/20 | 0.47 |
| ▸ | GCGR | P47871 | 6/20 | 0.46 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.46 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.46 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.46 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.46 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.46 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.46 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.46 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.46 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11999234 | 0.89 | ESR1 (0.62) | ESR1ESR2GCGRADCY6ADCY3 | |
| SCHEMBL2658018 | 0.83 | KMT2A (0.58) | ESR1ESR2LMNAMEN1ALDH1A1 | |
| SCHEMBL4027743 | 0.83 | ESR1 (0.58) | ESR1ESR2ESRRGESRRBLMNA | |
| SCHEMBL4677361 | 0.82 | ESR1 (0.85) | ESR1ESR2MDM4MDM2MIF | |
| SCHEMBL11999235 | 0.82 | ESR1 (0.54) | ESR1ESR2GCGRADCY6ADCY3 | |
| SCHEMBL2669617 | 0.82 | ESR1 (0.54) | ESR1ESR2GCGRADCY6ADCY3 | |
| SCHEMBL5877820 | 0.79 | ESR1 (0.47) | ESR1ESR2LMNAMEN1ALDH1A1 | |
| SCHEMBL2669746 | 0.79 | ESR1 (0.50) | ESR1ESR2GCGRADCY6ADCY3 | |
| SCHEMBL2659405 | 0.79 | KMT2A (0.53) | ESR1ESR2GCGRADCY6ADCY3 | |
| SCHEMBL2669616 | 0.78 | ESR1 (0.49) | ESR1ESR2GCGRADCY6ADCY3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8710236-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ESR1 1146/4885ESR2 694/4885ESRRG 529/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | ESR1 1034/4885ESR2 716/4885ESRRG 555/4885 |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ESR1 1070/4885ESR2 685/4885ESRRG 508/4885 |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | GLP1R, GCGR, GPR119 | ESR1 1070/4885ESR2 685/4885ESRRG 508/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | ESR1 1070/4885ESR2 685/4885ESRRG 508/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | ESR1 991/4885ESR2 698/4885ESRRG 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.